523 related articles for article (PubMed ID: 36737746)
1. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies.
Zheng D; Li N; Hou R; Zhang X; Wu L; Sundquist J; Sundquist K; Ji J
BMC Med; 2023 Feb; 21(1):40. PubMed ID: 36737746
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.
Douros A; Filion KB; Yin H; Yu OH; Etminan M; Udell JA; Azoulay L
Diabetes Care; 2018 Nov; 41(11):2330-2338. PubMed ID: 30150234
[TBL] [Abstract][Full Text] [Related]
3. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.
Kapoor I; Sarvepalli SM; D'Alessio D; Grewal DS; Hadziahmetovic M
Surv Ophthalmol; 2023; 68(6):1071-1083. PubMed ID: 37454782
[TBL] [Abstract][Full Text] [Related]
5. Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists.
Shiomi M; Takada T; Tanaka Y; Yajima K; Isomoto A; Sakamoto M; Otori K
J Diabetes Investig; 2019 Mar; 10(2):408-417. PubMed ID: 30033675
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
Jiao X; Peng P; Zhang Q; Shen Y
Clin Drug Investig; 2023 Dec; 43(12):915-926. PubMed ID: 37938535
[TBL] [Abstract][Full Text] [Related]
7. Correlation between diabetic retinopathy and diabetic nephropathy: a two-sample Mendelian randomization study.
Fang J; Luo C; Zhang D; He Q; Liu L
Front Endocrinol (Lausanne); 2023; 14():1265711. PubMed ID: 38027162
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I; Karagiannis T; Malandris K; Liakos A; Mainou M; Bekiari E; Matthews DR; Tsapas A
Diabetes Obes Metab; 2019 Jan; 21(1):188-193. PubMed ID: 30058208
[TBL] [Abstract][Full Text] [Related]
9. Associations of genetically determined lipid traits and lipid-modifying agents with the risk of diabetic retinopathy: A Mendelian randomization study.
Li N; Zhang X; Zhang M; Wu L; Li C; Pan Y; Wang W; Ji J; Zheng D
Atherosclerosis; 2023 Mar; 369():9-16. PubMed ID: 36827905
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's disease as a causal risk factor for diabetic retinopathy: a Mendelian randomization study.
Ouyang F; Yuan P; Ju Y; Chen W; Peng Z; Xu H
Front Endocrinol (Lausanne); 2024; 15():1340608. PubMed ID: 38699385
[TBL] [Abstract][Full Text] [Related]
11. The causal effect of obesity on diabetic retinopathy: A two-sample Mendelian randomization study.
Zheng C; Wei X; Cao X
Front Endocrinol (Lausanne); 2023; 14():1108731. PubMed ID: 37077358
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
Herrera Comoglio R; Vidal Guitart X
Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.
Igweokpala S; Sule NO; Douros A; Yu OHY; Filion KB
Diabetes Obes Metab; 2024 Feb; 26(2):721-731. PubMed ID: 38031234
[TBL] [Abstract][Full Text] [Related]
14. The potential benefits of glucagon-like peptide-1 receptor agonists for diabetic retinopathy.
Pang B; Zhou H; Kuang H
Peptides; 2018 Feb; 100():123-126. PubMed ID: 28807775
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
16. Statins as a risk factor for diabetic retinopathy: a Mendelian randomization and cross-sectional observational study.
Chen C; Zhang H; Lan Y; Yan W; Liu S; Chen Y; Xie T; Ning J; Yan X; Shang L; Han J
J Transl Med; 2024 Mar; 22(1):298. PubMed ID: 38520016
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like Peptide 1 Receptor Agonist use and the effect on diabetic retinopathy: An uncertain relationship.
Hui BTK; Yeong JL; Peto T; Willoughby CE
Peptides; 2024 Aug; 178():171240. PubMed ID: 38705472
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
Gaborit B; Julla JB; Besbes S; Proust M; Vincentelli C; Alos B; Ancel P; Alzaid F; Garcia R; Mailly P; Sabatier F; Righini M; Gascon P; Matonti F; Houssays M; Goumidi L; Vignaud L; Guillonneau X; Erginay A; Dupas B; Marie-Louise J; Autié M; Vidal-Trecan T; Riveline JP; Venteclef N; Massin P; Muller L; Dutour A; Gautier JF; Germain S
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31589290
[TBL] [Abstract][Full Text] [Related]
19. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
20. Genetic Evidence for Repurposing of GLP1R (Glucagon-Like Peptide-1 Receptor) Agonists to Prevent Heart Failure.
Daghlas I; Karhunen V; Ray D; Zuber V; Burgess S; Tsao PS; Lynch JA; Lee KM; Voight BF; Chang KM; Baker EH; Damrauer SM; Howson JMM; Vujkovic M; Gill D
J Am Heart Assoc; 2021 Jul; 10(13):e020331. PubMed ID: 34184541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
